176 related articles for article (PubMed ID: 23254420)
1. Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.
Speer A; Shrestha TB; Bossmann SH; Basaraba RJ; Harber GJ; Michalek SM; Niederweis M; Kutsch O; Wolschendorf F
Antimicrob Agents Chemother; 2013 Feb; 57(2):1089-91. PubMed ID: 23254420
[TBL] [Abstract][Full Text] [Related]
2. A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.
Gold B; Warrier T; Nathan C
Methods Mol Biol; 2021; 2314():611-635. PubMed ID: 34235673
[TBL] [Abstract][Full Text] [Related]
3. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
Gold B; Warrier T; Nathan C
Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
[TBL] [Abstract][Full Text] [Related]
4. 8-Hydroxyquinolines Are Boosting Agents of Copper-Related Toxicity in Mycobacterium tuberculosis.
Shah S; Dalecki AG; Malalasekera AP; Crawford CL; Michalek SM; Kutsch O; Sun J; Bossmann SH; Wolschendorf F
Antimicrob Agents Chemother; 2016 Oct; 60(10):5765-76. PubMed ID: 27431227
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
6. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
Silva-Miranda M; Ekaza E; Breiman A; Asehnoune K; Barros-Aguirre D; Pethe K; Ewann F; Brodin P; Ballell-Pages L; Altare F
Antimicrob Agents Chemother; 2015 Jan; 59(1):693-7. PubMed ID: 25348525
[TBL] [Abstract][Full Text] [Related]
7. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem.
Goldman RC
Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384
[TBL] [Abstract][Full Text] [Related]
8. Copper-related toxicity in replicating and dormant Mycobacterium tuberculosis caused by 1-hydroxy-5-R-pyridine-2(1H)-thiones.
Salina EG; Huszár S; Zemanová J; Keruchenko J; Riabova O; Kazakova E; Grigorov A; Azhikina T; Kaprelyants A; Mikušová K; Makarov V
Metallomics; 2018 Jul; 10(7):992-1002. PubMed ID: 29946601
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium tuberculosis High-Throughput Screening.
White EL; Tower NA; Rasmussen L
Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
[TBL] [Abstract][Full Text] [Related]
10. Selective Killing of Dormant Mycobacterium tuberculosis by Marine Natural Products.
Rodrigues Felix C; Gupta R; Geden S; Roberts J; Winder P; Pomponi SA; Diaz MC; Reed JK; Wright AE; Rohde KH
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607021
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis.
Ollinger J; Kumar A; Roberts DM; Bailey MA; Casey A; Parish T
PLoS One; 2019; 14(1):e0205479. PubMed ID: 30650074
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA
Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471
[TBL] [Abstract][Full Text] [Related]
13. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
[TBL] [Abstract][Full Text] [Related]
14. Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.
Early J; Ollinger J; Darby C; Alling T; Mullen S; Casey A; Gold B; Ochoada J; Wiernicki T; Masquelin T; Nathan C; Hipskind PA; Parish T
ACS Infect Dis; 2019 Feb; 5(2):272-280. PubMed ID: 30501173
[TBL] [Abstract][Full Text] [Related]
15. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
Karabanovich G; Zemanová J; Smutný T; Székely R; Šarkan M; Centárová I; Vocat A; Pávková I; Čonka P; Němeček J; Stolaříková J; Vejsová M; Vávrová K; Klimešová V; Hrabálek A; Pávek P; Cole ST; Mikušová K; Roh J
J Med Chem; 2016 Mar; 59(6):2362-80. PubMed ID: 26948407
[TBL] [Abstract][Full Text] [Related]
16. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis.
Zheng P; Somersan-Karakaya S; Lu S; Roberts J; Pingle M; Warrier T; Little D; Guo X; Brickner SJ; Nathan CF; Gold B; Liu G
J Med Chem; 2014 May; 57(9):3755-72. PubMed ID: 24694175
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial Susceptibility Testing for Mycobacterium sps in High-Throughput Format.
Pérez-Herrán E; Mendoza A
Methods Mol Biol; 2021; 2314():637-648. PubMed ID: 34235674
[TBL] [Abstract][Full Text] [Related]
18. A high throughput methodology for susceptibility testing of Mycobacterium tuberculosis isolates.
Rampersad T; Makume M; Sobia P; Willem Sturm A
J Microbiol Methods; 2018 Mar; 146():64-67. PubMed ID: 29410256
[TBL] [Abstract][Full Text] [Related]
19. Minding the gaps in tuberculosis research.
Ekins S; Nuermberger EL; Freundlich JS
Drug Discov Today; 2014 Sep; 19(9):1279-82. PubMed ID: 24993157
[No Abstract] [Full Text] [Related]
20. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
Coulibaly S; Cimino M; Ouattara M; Lecoutey C; Buchieri MV; Alonso-Rodriguez N; Briffotaux J; Mornico D; Gicquel B; Rochais C; Dallemagne P
Eur J Med Chem; 2020 Dec; 207():112821. PubMed ID: 32950907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
